All In Biotech

Drug Trial Radar · NCT07243080

Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention

Comparison Between the Efficacy of Rivaroxaban vs Enoxaparin in Post-Operative Deep Venous Thrombosis Prophylaxis After Exploratory Laparotomy

Last checked: Nov 20, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 212 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

212

Planned (sponsor's estimate)

Start

Oct 10, 2025

Primary completion

Nov 10, 2025

Study completion Nov 15, 2025

Sponsor

Lead sponsor
Mayo Hospital LahoreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
King Edward Medical University
First posted
Nov 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if rivaroxaban works better than enoxaparin to prevent deep vein thrombosis (DVT) after emergency exploratory laparotomy in adults. It will also learn about the safety of rivaroxaban compared to enoxaparin. The main questions it aims to answer are: Does rivaroxaban lower the number of patients who develop DVT after exploratory laparotomy compared to enoxaparin? What medical problems or side effects do participants have when taking rivaroxaban versus enoxaparin? Researchers will compare rivaroxaban (an oral anticoagulant) to enoxaparin (a subcutaneous injection) to see which drug works better to prevent blood clots after surgery. Participants will: Take rivaroxaban 10 mg orally once daily for 7 days, or enoxaparin 40 mg subcutaneously once daily for 7 days after surgery Undergo duplex color Doppler ultrasound scans of the legs on day 5 and day 10 after surgery Be monitored for bleeding, complications, and other side effects

Conditions

  • Deep Venous Thromboses
  • Laparotomy Patients

Interventions

  • rivaroxaban (10mg)Drug

    Name: Drug: Rivaroxaban Type: Drug Description: Participants receive rivaroxaban 10 mg orally once daily for 7 days following emergency exploratory laparotomy. All patients also receive standard perioperative management and mechanical prophylaxis as per institutional guidelines.

  • Enoxaparin 40 mg SCDrug

    Name: Drug: Enoxaparin Type: Drug Description: Participants receive enoxaparin 40 mg subcutaneously once daily for 7 days following emergency exploratory laparotomy. All patients also receive standard perioperative management and mechanical prophylaxis as per institutional guidelines.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Deep Vein Thrombosis (DVT)Time frame: Postoperative Day 5 and Day 10

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Hospital Lahore

    Lahore, Punjab Province, Pakistan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.